Cargando…

Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer

INTRODUCTION: Deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) is associated with an improved prognosis in colon cancer stage II but poor prognosis in stage IV colon cancer. The clinical significance of dMMR in colon cancer stage III is not established. METHODS: Tissue mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hestetun, Kjersti Elvestad, Rosenlund, Nina Benedikte, Stanisavljević, Luka, Dahl, Olav, Myklebust, Mette Pernille
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468812/ https://www.ncbi.nlm.nih.gov/pubmed/36110945 http://dx.doi.org/10.3389/fonc.2022.853545

Ejemplares similares

Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer
por: Jacob, Havjin, et al.
Publicado: (2017)

A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer
por: Jacob, Havjin, et al.
Publicado: (2018)

Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis
por: Myklebust, Mette Pernille, et al.
Publicado: (2019)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
por: Zhang, Chunze, et al.
Publicado: (2022)

The impact of mismatch repair status and systemic inflammatory markers on radiological staging in colon cancer
por: Platt, James R, et al.
Publicado: (2023)

Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study
por: Myklebust, Mette Pernille, et al.
Publicado: (2021)

Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
por: Zhan, Yixiang, et al.
Publicado: (2023)

Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
por: Tomasello, Gianluca, et al.
Publicado: (2022)

Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer
por: Sasaki, Yusuke, et al.
Publicado: (2016)

Analysis of the Clinicopathological Characteristics of Stage I–III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins
por: Liang, Yichao, et al.
Publicado: (2021)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population‐based series and a randomized phase III study on adjuvant chemotherapy
por: Boye, Kjetil, et al.
Publicado: (2016)

Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinoma—a systematic review and meta-analysis
por: Davey, Matthew G., et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
por: Taieb, J., et al.
Publicado: (2019)

Prognostic Value and Immunohistochemical Analysis of Mismatch Repair Deficiency in Patients with Stage II and III Colorectal Carcinoma—A Single-Center Study
por: Denčić, Tijana, et al.
Publicado: (2020)

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients
por: van den Broek, Evert, et al.
Publicado: (2016)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer
por: Shanmugam, Chandrakumar, et al.
Publicado: (2011)

Immunoscore(®) as a predictor of response to chemotherapy in stage II and stage III colon cancer
por: Mlecnik, Bernhard, et al.
Publicado: (2015)

Clinical Score to Predict Recurrence in Patients with Stage II and Stage III Colon Cancer
por: Viñal, David, et al.
Publicado: (2022)

Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study
por: Kang, Byung Woog, et al.
Publicado: (2021)

The Prognostic Value of Deficient Mismatch Repair in Stage II–IVa Nasopharyngeal Carcinoma in the Era of IMRT
por: Chen, Fang-ming, et al.
Publicado: (2020)

Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial Cancer
por: Chaowiwatkun, Kamonporn, et al.
Publicado: (2023)

Significance of the Lymph Node Ratio in Stage III Colon Cancer
por: Telian, Simon H., et al.
Publicado: (2008)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
por: Yunlong, Wu, et al.
Publicado: (2022)

Prognostic impact of high-risk factors and KRAS mutation in patients with stage II deficient mismatch repair colon cancer: a retrospective cohort study
por: Zhang, Yuting, et al.
Publicado: (2022)

DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection
por: Sugiyama, Tomohiro, et al.
Publicado: (2020)

DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands
por: Walker, Romy, et al.
Publicado: (2023)

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer
por: Mayanagi, Shuhei, et al.
Publicado: (2018)

Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers
por: Yoon, Harry H., et al.
Publicado: (2018)

Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas
por: Schem, Baard-Christian, et al.
Publicado: (2022)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

Diffusion and Binding of Mismatch Repair Protein, MSH2, in Breast Cancer Cells at Different Stages of Neoplastic Transformation
por: Sigley, Justin, et al.
Publicado: (2017)

Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer
por: Sarasqueta, C., et al.
Publicado: (2019)

The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer
por: Oltedal, Satu, et al.
Publicado: (2018)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_sj6nc8329ugavlb57mg8qr45ma